A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza

Inclusion Criteria:

• Patient understands the procedures and requirements and is willing and able to giveinformed consent for full participation in the study

• Adults, male or female, aged 18 to 60 years at time of consent.

• Early symptomatic Influenza (A or B); at least one reported symptom of influenza (including fever, history of fever, myalgias, headache, cough, fatigue, nasalcongestion, rhinorrhoea and sore throat) within 4 days (96 hours)

• Influenza positive by rapid antigen test OR a positive RT-PCR test for influenzaviruses within the last 24hrs with a Ct value of <30

• Able to walk unaided and unimpeded in activities of daily living (ADLs)

• Agrees and is able to adhere to all study procedures, including availability andcontact information for follow-up visits

Exclusion Criteria:

The patient may not enter the study if ANY of the following apply:

• Taking any concomitant medications or drugs which could interact with the studymedications or have antiviral activity

• Presence of any chronic illness/condition requiring long term treatment or othersignificant comorbidity

• BMI ≥35 Kg/m2

• Clinically relevant laboratory abnormalities discovered at screening

• Haemoglobin <10g/dL

• Platelet count <100,000/uL

• ALT > 2x ULN

• Total bilirubin >1.5 x ULN

• eGFR <70mls/min/1.73m2

• For females: pregnancy, actively trying to become pregnant or lactation (healthywomen on OCP are eligible to join)

• Contraindication to taking, or known hypersensitivity reaction to any of theproposed therapeutics

• Currently participating in another interventional influenza or COVID-19 therapeutictrial

• Clinical evidence of pneumonia- e.g. shortness of breath, hypoxaemia, crepitations (imaging not required)

• Known to be currently co-infected with SARS-CoV-2 (i.e. confirmed with positive ATKor RT-PCR)

• Received live attenuated influenza virus vaccine within 3 weeks prior to study entry